Image source: Getty Images.
Continue Reading Below
bluebird bio (NASDAQ: BLUE) closed down 13% Friday after presenting an update on its LentiGlobin programs and other research and development projects at its Gene Therapy Day yesterday.
R&D days are supposed to be a place for biotechs to showcase what they're working on, and they usually don't have a negative effect on the company's stock price. In fact, Bluebird's shares closed flat yesterday.
It appears today's decline comes from investors selling the news. Shares had run up in anticipation of the data release, so it shouldn't be much of a surprise that traders are selling now that there isn't another near-term catalyst.
Continue Reading Below
At least one analyst, Elemer Piros from Cantor Fitzgerald, downgraded Bluebird, arguing that the upcoming American Society of Hematology (ASH) meeting in December will be a non-event.
Technically, Piros is right. Bluebird changed the manufacturing process for its LentiGlobin gene therapy, increasing the number of cells that took up the gene to be expressed by threefold. More cells expressing LentiGlobin should result in more patients being cured of their transfusion-dependent beta-thalassemia and severe sickle cell disease, which the gene therapy treats.
The switch to the new manufacturing process happened recently, so the data at ASH comes from the old process. But that was known well before Bluebird's R&D day yesterday, so it doesn't seem like a reason to sell.
You could argue that Bluebird is in a no-lose situation going into ASH. All the old manufacturing process needs to do is produce decent -- but not necessarily outstanding -- results and investors should be convinced that the new process will likely put it over the edge. If the results are disappointing, Bluebird can argue that the new manufacturing process is so much better than the old one that the disappointing results aren't relevant.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Bluebird Bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.